TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS)

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Arvinas, Inc.
Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS)

Arvinas will present multiple research abstracts about vepdegestrant, an investigational drug for estrogen receptor positive breast cancer, at the San Antonio Breast Cancer Symposium in December 2025. The drug is being co-developed with Pfizer and is currently under FDA review.

Insights
QCOM   negative

Topped estimates but slid about 5% after weaker licensing revenue guidance


ARVN   positive

Company is presenting multiple research abstracts, has collaborative partnership with Pfizer, and is advancing a promising drug through FDA review